CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


[TIMP-2]*[IGFBP-7]Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug57 ACEIs Wiki 1.00
drug663 Conventional treatment Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.24

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.24

There is one clinical trial.

Clinical Trials


1 Urinary Biomarkers (TIMP-2 and IGFBP7) for Early Diagnostic Assessment of Acute Kidney Injury in Patients With SARS-CoV-2 (COVID-19)

Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.

NCT04393428 COVID-19 Renal Replacement Therapy Acute Kidney Injury Other: [TIMP-2]*[IGFBP-7]
MeSH:Acute Kidney Injury
HPO:Acute kidney injury

Primary Outcomes

Description: Sensibility and specificity of urinary [TIMP-2]*[IGFBP-7] > 0,3 to predict AKI (KDIGO stage ≥ 1) in SARS-CoV-2 patients at day-7 after measurement

Measure: Sensibility and specificity of urinary

Time: Occurence of AKI 7 days after urinary biomarkers measurement

Secondary Outcomes

Description: Sensibility and specificity of urinary [TIMP-2]*[IGFBP-7] > 0,3 to predict AKI worsening, renal replacement therapy requirement or persistant AKI

Measure: Sensibility and specificity of urinary

Time: Occurnce of AKI worsening, renal replacement therapy requirement or persistant AKI, 7 days after urinary biomarkers mesurement


Related HPO nodes (Using clinical trials)